Radiation levels outside a patient undergoing 177Lu-PSMA radioligand therapy

被引:0
|
作者
Li, Huan [1 ]
Liu, Haikuan [1 ]
Zhang, Weiyuan [1 ]
Lin, Xin [1 ]
Li, Zhiling [1 ]
Zhuo, Weihai [1 ]
机构
[1] Fudan Univ, Inst Radiat Med, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Lu-177-PSMA; radioligand therapy; extracorporeal radiation level; Monte Carlo simulation; PROSTATE-CANCER; SAFETY;
D O I
10.1088/1361-6498/ad3835
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Understanding the spatial distribution of radiation levels outside of a patient undergoing Lu-177 radioligand therapy is not only helpful for conducting correct tests for patient release, but also useful for estimation of its potential exposure to healthcare workers, caregivers, family members, and the general public. In this study, by mimicking the Lu-177-labeled prostate-specific membrane antigen radioligand therapy for prostate cancers in an adult male, the spatial distribution of radiation levels outside of the phantom was simulated based on the Monte Carlo software of Particle and Heavy Ion Transport System, and verified by a series of measurements. Moreover, the normalized dose rates were further formulized on the three transverse planes representing the heights of pelvis, abdomen and chest. The results showed that the distributions of radiation levels were quite complex. Multi-directional and multi-height measurements are needed to ensure the external dose rate to meet the release criteria. In general, the radiation level was higher at the horizontal plane where the source was located, and the levels in front and behind of the body were higher than those of the left and right sides at the same height. The ratio of simulated dose rates to measured ones ranged from 0.82 to 1.19 within 1 m away from the body surface in all directions. Based on the established functions, the relative root mean square deviation between the calculated and simulated values were 0.21, 0.25 and 0.23 within a radius of 1 m on the pelvis, abdomen and chest transverse planes, respectively. It is expected that the results of this study would be helpful for guiding the test of extracorporeal radiation to determine the patient's release, and of benefit to estimate the radiation exposure to others.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [42] Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
    Grubmueller, Bernhard
    Senn, Daniela
    Kramer, Gero
    Baltzer, Pascal
    D'Andrea, David
    Grubmueller, Karl Hermann
    Mitterhauser, Markus
    Eidherr, Harald
    Haug, Alexander R.
    Wadsak, Wolfgang
    Pfaff, Sarah
    Shariat, Shahrokh F.
    Hacker, Marcus
    Hartenbach, Markus
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1063 - 1072
  • [43] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
    Abuqbeitah, Mohammad
    Demir, Mustafa
    Uslu-Besli, Lebriz
    Yeyin, Nami
    Sonmezoglu, Kerim
    RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2018, 57 (01) : 55 - 61
  • [44] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
    Mohammad Abuqbeitah
    Mustafa Demir
    Lebriz Uslu-Beşli
    Nami Yeyin
    Kerim Sönmezoğlu
    Radiation and Environmental Biophysics, 2018, 57 : 55 - 61
  • [45] Effective half-life, excretion and radiation exposure of 177Lu-PSMA
    Parlak, Yasemin
    Mutevelizade, Gozde
    Sezgin, Ceren
    Goksoy, Didem
    Gumuser, Gul
    Sayit, Elvan
    RADIATION PROTECTION DOSIMETRY, 2023, 199 (10) : 1090 - 1095
  • [46] Radiation exposure in 177Lu-PSMA & the possibility of applying outpatient treatment rules
    Abuqbeitah, M.
    Demir, M.
    Yeyin, N.
    Uslu, L.
    Vatankulu, B.
    Kabasakal, L.
    Sonmezoglu, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S201 - S201
  • [47] Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during 177Lu-based radionuclide therapy: a study for 177Lu-DOTATATE and 177Lu-PSMA
    Gosewisch, A.
    Ermoschkin, L.
    Ilhan, H.
    Todica, A.
    Vamacka, L.
    Bartenstein, P.
    Boening, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S270 - S271
  • [48] Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
    Gafita, Andrei
    Rauscher, Isabel
    Retz, Margitta
    Knorr, Karina
    Heck, Matthias
    Wester, Hans-Juergen
    D'Alessandria, Calogero
    Weber, Wolfgang A.
    Eiber, Matthias
    Tauber, Robert
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) : 644 - 648
  • [49] Medical Event: Accidental Oral Administration of 177Lu-PSMA to a Patient With Hyperthyroidism
    Moghadam, Soroush Zarehparvar
    Aghaee, Atena
    Esmatinia, Mohamad
    Nateghi, Navid
    Aryana, Kamran
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (06) : 439 - 441
  • [50] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)